Relapsed leukemia following initial therapeutic response and remission is difficult to treat and causes high patient mortality. Leukemia relapse is due to residual quiescent leukemia cells that escape conventional therapies and later reemerge. Eliminating not only growing but quiescent leukemia cells is critical to effectively treating leukemia and preventing its recurrence. Such therapeutic agents, however, are lacking in the clinic. Here we report that a 4-arylmethyl derivative of the natural anticancer compound curcumin demonstrates a dual effect in eliminating both growing and quiescent leukemia cells. This curcumin derivative, C212, on the one hand, inhibits growing leukemia cells at a higher efficacy than curcumin by inducing apoptosis and cell cycle arrest; it, on the other hand, kills quiescent leukemia cells that are resistant to conventional chemotherapy drugs. Furthermore, C212 drives leukemia cells into and kills them at deep quiescence, avoiding the potential risk associated with awaking therapy-resistant subpopulation of quiescent leukemia cells. Lastly, we show that C212 induces apoptosis and drives cells into deep dormancy at least partially by binding to and inhibiting Hsp90, leading to client protein degradation and protein aggregation. Further elucidating the molecular mechanisms underlying the dual function of C212 in eliminating both growing and quiescent leukemia cells will aid the development of novel therapies against leukemia relapse.
Introduction
Conventional anti-cancer drugs target fast-growing cells and induce cell death or cell cycle arrest.
These drugs are ineffective against slow-growing or quiescent cancer cells that do not exhibit active DNA replication and cell division. Accordingly, quiescent cancer cells, including but not limited to cancer stem cells, escape conventional chemotherapies; they often reemerge after a period of dormancy, causing cancer relapse and metastasis that are exceedingly difficult to treat and leading to high patient mortality [1] [2] [3] .
The ability to target and eliminate both growing and quiescent cancer cells is critical to treating cancer and preventing cancer recurrence. We now have a long list of chemotherapy drugs that kill growing cancer cells, but still lack therapeutic agents that effectively eliminate quiescent cancer cells in the clinic. How to eradicate quiescent slow-growing cancer cells has only begun to be explored, primarily from metabolic and epigenetic angles [4] [5] [6] [7] . Recently, we have identified two natural compounds, ergosterol peroxide and ganodermanondiol, from the medical mushroom Ganoderma lucidum. We have shown that these two compounds eliminate quiescent slow-cycling cells by pushing cells to shallow quiescence and exposing them to cytotoxic effects 8 . Awaking quiescent cancer cells to kill presents a potential strategy to prevent cancer recurrence 9 . However, if some of these quiescent cancer cells develop and acquire therapy resistance during dormancy 10, 11 , waking them can be risky.
In this study, we show that a curcumin derivative, C212, exhibits potent cytotoxicity against not only growing leukemia cells but quiescent counterparts without waking them up. Curcumin (diferuloylmethane) is the primary natural polyphenol found in the rhizome of Curcuma longa (turmeric) and others Curcuma spp 12 . It exhibits pharmacological effects on metabolic, cardiovascular, neurological, hepatic, and respiratory disorders 12, 13 ; it also inhibits cancer growth in the reproductive, digestive, urinary, pulmonary, nervous, skeletal, skin, lymphatic, and immune systems, attributing to its immunomodulatory, anti-inflammatory, antioxidant, pro-apoptotic, and antiangiogenic properties 14, 15 . At the molecular level, curcumin interacts with multiple cellular pathways: it inhibits NF-κB, Akt/PI3K, and MAPK pathways and enhances p53 activity, to name a few 15, 16 .
Recent work, including ours, showed that curcumin suppresses tumor growth by inhibiting heat shock protein 90 (Hsp90) and down-regulating Hsp90 client proteins [17] [18] [19] . Hsp90 is a molecular chaperone that is highly conserved and abundant in cells of virtually every organism; it interacts with and assists the proper folding of a large and diverse group of client proteins that are critical to cellular functions, many of which are kinases and transcription factors 20 . Increased activities of Hsp90 and client proteins enhance cellular homeostasis against stressful conditions-and in the case of cancer, enhance cancer cell survival 21, 22 . Accordingly, small molecular drugs that target Hsp90 have shown anticancer effects [23] [24] [25] .
Following the anticancer effect of curcumin, especially in inhibiting Hsp90, we have designed and synthesized curcumin derivatives that preserve Hsp90 inhibition and increase compound bioavailability and anticancer efficacy 19, 26, 27 . Here we report that a novel curcumin derivative C212 binds to Hsp90 and inhibits Hsp90 function, inducing client protein degradation and cell apoptosis.
C212 exhibits a dual function in eliminating both growing and quiescent cancer cells, as we show in two leukemia cell lines HL-60 and K562. Furthermore, C212 eliminates quiescent leukemia cells in their deep dormancy and thus avoids the risk of prematurely waking them up, presenting an attractive approach to prevent leukemia recurrence.
Result:
C212 inhibits growing cancer cell viability by inducing apoptosis and G2/M arrest C212, (1E,6E)-4-(2-Chlorinebenzyl)-1,7-bis(3-pyridine)-1,6-heptadiene-3,5-dione ( Fig. S1A) , was synthesized as one of several 4-arylmethyl curcumin analogues in our previous study 28 . Here we applied C212 and curcumin to a variety of cancer cell lines, including leukemia (HL-60 and K562), colon cancer (HCT116, SW620, and HT29), breast cancer (MCF-7), gastric cancer (SGC7901), and liver cancer (HepG2). We found that both C212 and curcumin dose-dependently suppressed cell viability in these cancer cell lines as tested in MTS assays ( Fig. 1 A-H). Furthermore, C212 exhibited a lower IC50 (the concentration required to inhibit cell growth by 50%) than that of curcumin in each tested cell line, showing significantly stronger anticancer effects ( Fig. 1 A-H and Table 1 ). Among the tested cell lines, leukemia cells (HL-60 and K562) as a group were the most sensitive to C212 (Table 1 ) and thus were focused on in the further study.
The inhibitory effect of C212 on leukemia cell viability is at least twofold. First, C212 dose-dependently induced apoptosis in HL-60 and K562 cells. With an increasing C212 concentration, 1) the subpopulation of cells exhibiting the characteristic externalization of inner membrane phospholipids (Annexin V-positive) and membrane compromise (PI-positive) increased monotonically in K562 ( Fig. 2A , top) and HL-60 cells ( Fig. 2A, bottom) ; 2) the subpopulation of cells exhibiting the characteristic depolarized mitochondrial membrane potential (with reduced red fluorescence of JC-1 staining) increased monotonically in K562 ( 
C212 eliminates quiescent leukemia cells in contrast to chemotherapy drugs
Different from growing cells, quiescent cells are resistant to conventional chemotherapies that target cell proliferation machinery such as DNA replication and cell division. To test the cytotoxicity of C212 on quiescent leukemia cells, we first induced HL-60 and K562 cells to quiescence or a slow-growing state by serum starvation: a 12-hour serum starvation reduced the percentage of actively replicating (EdU+%) HL-60 cells from 98.3% in growing condition to 8.1% (Fig. 3A) ; for K562 cells, which appeared to be less sensitive to serum growth signals than HL-60, a 36-hour serum starvation reduced EdU+% from 98.8% in growing condition to 22.5% ( Fig. 3B ). As expected, chemotherapy drugs were inefficient in killing quiescent and slow-growing leukemia cells: the lethal concentrations to kill half of quiescent cell population (LC50q) with paclitaxel, topotecan, and doxorubicin treatments were typically several folds higher than those of proliferating cell population Table 2 ). By contrast, C212 exhibited the same LC50q and LC50p (2.6 µM) in HL-60 cells, suggesting its equal effectiveness in killing both quiescent and proliferating HL-60 cells. Moreover, C212 showed even stronger cytotoxicity in quiescent K562 cells than proliferating counterparts-its LC50q (2.7 µM) was about 3-fold lower than LC50p (7.6 µM). Put together, C212 appeared to effectively eliminate quiescent leukemia cells in contrast to commonly used chemotherapy drugs.
C212 drives leukemia cells into deep quiescence
It has been previously reported that arsenic trioxide (As2O3) and certain cytokines (IFN-α, G-CSF) were able to sensitize quiescent leukemia cells to chemotherapy cytotoxicity by reducing quiescence depth and waking them up 29 . Correspondingly, we examined whether C212 altered cell quiescence depth and killed quiescent leukemia cells. To measure quiescence depth, we first induced leukemia cells into quiescent or a slow-growing state by serum starvation (for 12 hours in HL-60 and for 36 hours in K562, same as in Fig. 3 ); we then stimulated cells with serum (2.5%) and checked the percentages of cells that exited quiescence and re-entered the cell cycle (EdU+): deeper quiescent cells would be harder to exit quiescence and thus have smaller EdU+% than shallower cells. When treatment at increasing sublethal doses drove leukemia cells into deeper quiescence, and thus a smaller subpopulation of quiescent cells was able to exit quiescence and re-enter the cell cycle given the same serum-stimulation condition (2.5%).
We further examined whether the effect of C212 to drive leukemia cells to deeper quiescence was exerted during serum starvation or stimulation or both. Our previous studies showed that quiescence depth is determined by the serum threshold to activate an Rb-E2F bistable gene switch in the cell; such a serum threshold can be modulated by various cellular activities in quiescence (during serum starvation) and quiescence exit (serum stimulation) 30, 31 . When C212 was included in the last segment of serum starvation but not the serum stimulation phase, cell cycle re-entry was not affected in HL-60 cells (EdU+% upon serum stimulation showed no statistically significant difference with or without C212; Fig. 4C ) and was affected only slightly in K562 cells (EdU+% upon serum stimulation showed a statistically significant difference only at 2 μM C212 over control; Fig. 4D ).
When C212 was included in the serum stimulation phase but not in the last segment of serum starvation, cell cycle re-entry was affected significantly in both HL-60 and K562 cells and EdU+% upon serum stimulation decreased in a C212 dose-dependent manner ( Fig. 4 E and F) . Put together, our data suggested that C212 drove leukemia cells into deep quiescence, and it exerted this quiescence-deepening effect primarily by increasing the serum threshold during quiescence exit.
C212 inhibits Hsp90 inducing client protein degradation and protein aggregation
As found in our previous work 17 , curcumin binds to the α-helix domain of Hsp90 at multiple residues ( Fig. S2 A and C) and inhibits the function of Hsp90 in properly folding client proteins-e.g., kinases that participate in cell proliferation. C212 was also predicted to bind to Hsp90 based on molecular docking analysis between C212 and the C-and N-terminus of Hsp90 ( Fig. S2 B and D) . When we carried out fluorescence quenching experiments with purified Hsp90 protein, we found that C212 dose-dependently quenched the intrinsic fluorescence of Hsp90 (excitation/emission = 280/337 nm), which was accompanied with blueshifts of λem curves (Fig. 5A) . Specifically, the titration curves of C212 with the N-terminus, middle (M-)region, and C-terminus of Hsp90 yielded estimated dissociation constants (Kd) of 36.3, 36.9, and 15.3, respectively ( Table 3 ), suggesting that C212 interacted with Hsp90.
Through binding to Hsp90, C212, like curcumin, was expected to interfere with the Hsp90 function in folding and stabilizing client proteins. Indeed, in both K562 and HL-60 cells treated with C212, protein levels of Hsp90 clients Raf, Akt, Erk, and Mek, particularly in their phosphorylated forms, decreased in a C212 dose-dependent manner ( Fig. 5 B & C) . The C212-induced decreases of Hsp90 client protein levels were at least partially dependent on proteasome-mediated degradation, which could be rescued by co-treating cells with a proteasome inhibitor MG132 (Fig. S2E ).
We also found that C212 treatment induced the formation of protein aggregates. As seen in both HL-60 ( Fig. 5D ) and K562 cells (Fig. 5E ) induced to quiescence by serum starvation, the degree of protein aggregation (as measured by ProteoStat staining) increased in a C212 dose-dependent manner. This result was consistent with the notion that C212 interferes with Hsp90 function, which may lead to the accumulation of misfolded proteins. Non-degraded misfolded protein and aggregates are linked to diseases such as aging-related neurodegeneration and systemic amyloidosis [32] [33] [34] . Very recently, protein aggregates have been identified to drive deep cellular dormancy in both bacteria and neural stem cells 35, 36 . The role of C212 to inhibit Hsp90 and induce protein aggregation thus likely contributes to its role inducing deep quiescence in leukemia cells (Fig. 5F ).
Discussion
In this study, we found that C212, a 4-arylmethyl curcumin derivative demonstrates a dual anticancer effect: it not only inhibits the viability of growing cancer cells by inducing apoptosis and G2/M cell cycle arrest, but eliminates quiescent leukemia cells that are resistant to conventional chemotherapy drugs such as paclitaxel, doxorubicin, and topotecan that preferentially kill fast-growing cells. This dual effect of C212 presents a novel class of cancer therapeutic strategy, particularly in preventing leukemia recurrence caused by residual quiescent leukemia cells.
Quiescence is a reversible cellular dormancy state that can persist over prolonged periods.
Leukemia relapse, despite initial therapeutic responses and remissions, is often due to the reemergence of residual quiescent cells, including leukemia stem cells 19, [37] [38] [39] [40] . Therefore, effective therapies targeting and eliminating quiescent leukemic cells are critical to preventing leukemia relapse. In this regard, cytokines such as IFN-α and G-CSF, as well as arsenic trioxide As2O3, have been shown to wake up quiescent leukemia stem cells and sensitize them to chemotherapy 29 .
However, some quiescent leukemia cells during long-term dormancy under stressful conditions can undergo genetic or epigenetic changes and further develop resistance to follow-up therapies 10, 11 .
Awakening these quiescent leukemia cells will cause a risk.
C212 presents a safer strategy to prevent leukemia relapse as it pushes quiescent leukemia cells into and kills them at a deep dormancy, instead of waking them up. The effect of C212 to induce deep quiescence is at least partially due to its binding to Hsp90 and inhibiting Hsp90 function. Hsp90 is an evolutionarily conserved molecular chaperone that participates in stabilizing and activating more than 200 client proteins 20, 41 . Inhibiting Hsp90 function leads to misfolded client proteins that are often insoluble and aggregate under physiological conditions. Accumulation of protein aggregates has been recently found to drive deep cell dormancy in both neural stem cells and bacteria 35, 36 . Consistently, C212 dose-dependently induces protein aggregation ( Fig. 5 D and E) and drives quiescent leukemia cells into deeper dormancy at sublethal doses (Fig. 4) .
Previously, we have found that by inhibiting Hsp90, curcumin and its derivatives induce the degradation of client protein P210 bcr/abl and correspondingly the growth arrest and apoptosis of leukemia cells 17, 19, 27 . Similarly, C212 binds to and inhibits Hsp90, induces the degradation of Hsp90 client proteins in a dose-dependent manner in leukemia cell lines K562 and HL-60 ( Fig. 5 B and C) .
Consistent with the apoptosis-inducing effect of inhibiting Hsp90 42 , C212 induces apoptosis in K562
and HL-60 cells (Fig. 2) .
Inhibiting Hsp90 does not solely account for the effects of C212 in eliminating quiescent leukemia cells. When we targeted to inhibit Hsp90 using 17-AAG, a classic Hsp90 inhibitor, we found proliferating cells, instead of quiescent cells, were preferentially eliminated in both leukemia cell lines K562 and HL-60 (Fig. S3 ). This result suggests that the preferential killing effects of C212 on quiescent leukemia cells involve cellular targets beyond Hsp90, which is consistent with a broad spectrum of molecular targets known to curcumin 15, 16 . Further identifying the molecular mechanisms of C212 in eliminating both quiescent and growing leukemia cells will help further develop and improve treatment strategies against leukemia relapse.
Materials and methods:
Reagents. C212 was synthesized in our laboratory as described previously 28 24010043 ). HL-60 cells were then cultured in starvation medium for 12 hours, and K562 cells for 36 hours. To induce quiescence exit and cell cycle re-entry, cells were switched to serum stimulation medium: HL-60, DMEM (with glutamine) containing 2.5% BGS; K562, EBSS containing 2.5%
BGS.
Cell viability MTS assay. Leukemia cells were seeded in 96-well plates and cultured in 100 μl medium for the time indicated. Cells were then treated with C212 or chemotherapy drugs for 48 hours; 20 μl CellTiter stock solution (Promega, G3510) was added into each well, followed by a 3-hour incubation at 37 ℃. The absorbance of each well was measured at 490 nm, with the absorbance of wells containing medium and CellTiter only set as the background control (Abackground) and the absorbance of wells containing cells treated with vehicle set as the vehicle control (Acontrol).
Cell viability = (Atreatment -Abackground)/( Acontrol -Abackground)*100%.
Cell proliferation assays. To assess DNA content, leukemia cells were spun down and resuspended in 500 μl 70% ethanol for overnight at -20 ℃; cells were then washed once with 300 μl cold DPBS, resuspended in 300 μl DNA-staining solution containing propidium iodide (PI; Sigma, P4170) and
RNase A (Sigma, R6513) at final concentrations of 50 μg/ml in DPBS, incubated in the dark for 30 min at 37 ℃, followed by PI intensity measurement using flow cytometry. To assess EdU incorporation during DNA synthesis after cell cycle re-entry from quiescence, 2 μM EdU was included in serum stimulation medium for 43 and 24 hours, respectively, for HL-60 and K562 cells, K562 (E) cells that were serum-starved as in Fig. 3 to induce quiescence/slow-growth were further treated with C212 at the indicated doses for 30 and 36 hours, respectively, then subjected to fluorescence-based protein aggregation assay using ProteoStat. Error bar, SEM (n = 2); *P < 0.05, **P < 0.01 (1-tailed t test). (F) A proposed model of C212 that deepens quiescence of leukemia cells and increases the serum threshold for quiescence exit. 
